Neutralizing murine monoclonal anti-interleukin-10 antibodies enhance binding of antibodies against a different epitope

Mol Immunol. 1996 Oct;33(14):1103-11. doi: 10.1016/s0161-5890(96)00072-7.

Abstract

Fifteen murine hybridoma lines that produce monoclonal antibodies against human interleukin-10 (IL-10), which is one of the most important regulatory cytokines of the immune system, were raised. Twelve of these antibodies, all in the class IgG1/kappa, recognize three groups of epitopes: A, B and C. All antibodies in these groups inhibit binding of antibodies of the same group to IL-10 and none of them inhibit binding of an antibody of another group. Two IgM/kappa antibodies and one IgG1/kappa antibody, with low affinity, have distinct binding properties and cannot be assigned to one of these groups. Antibodies from all three epitope groups inhibit the biological activity of IL-10. The three antibodies of group A neutralize IL-10 in an approximately equimolar ratio, at concentrations as low as 10 pM. In addition to their high neutralizing capacity, antibodies of group A enhance the binding of antibodies of group C to IL-10. The on-rate of binding of the two antibodies CB/RS/10 and 11 (group C) increased five- to seven-fold, when one of the antibodies CB/RS/1, 2 or 14 (group A) is bound to IL-10.

MeSH terms

  • Adjuvants, Immunologic / pharmacology*
  • Animals
  • Antibodies, Monoclonal / immunology*
  • Antibodies, Monoclonal / pharmacology*
  • Binding, Competitive / immunology
  • Drug Synergism
  • Epitope Mapping / methods*
  • Epitopes / immunology*
  • Female
  • Humans
  • Interleukin-10 / immunology*
  • Mice
  • Mice, Inbred BALB C
  • Tumor Necrosis Factor-alpha / immunology
  • Up-Regulation / immunology*

Substances

  • Adjuvants, Immunologic
  • Antibodies, Monoclonal
  • Epitopes
  • Tumor Necrosis Factor-alpha
  • Interleukin-10